How exactly will health systems pay for these powerful yet ultra-expensive therapies? The list price on Kymriah, for instance, sits at $373,000 for its diffuse large B cell lymphoma indication and $475,000 for its acute lymphoblastic leukemia indication.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,